Drug
Botulinum Toxin Neuromodulator
Botulinum Toxin Neuromodulator: highest development phase Phase 3, developed by Galderma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Galderma
Trials
| Drug | Phase | Indication |
|---|---|---|
| botulinum toxin neuromodulator NCT04225260 | Phase 3 | Glabellar Lines |
Latest
No recent events.
Follow Botulinum Toxin Neuromodulator on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.